Clinical Trials for Colon Cancer

Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors and specified RAS alterations (or HRAS-overexpressing head and neck squamous cell carcinoma) receive darlifarnib, an investigational farnesyltransferase inhibitor, alone. Combination cohorts pair darlifarnib with cabozantinib for renal cell carcinoma previously treated with immunotherapy or with adagrasib for previously treated KRAS G12C-mutant lung, colorectal, or pancreatic cancer.

ClinicalTrials.gov ID: NCT06026410

A Phase 1/2a, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, unresectable or metastatic KRAS G12D-mutated solid tumors receive oral VS-7375, an investigational inhibitor of active and inactive KRAS G12D, alone or with the anti-EGFR antibody cetuximab. Expansion cohorts focus on pancreatic cancer and NSCLC for monotherapy and colorectal cancer for the combination; prior direct KRAS G12D inhibitor treatment is excluded.

ClinicalTrials.gov ID: NCT07020221

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: This trial enrolls adults with stage IV solid tumors—including NSCLC, colorectal, breast, or bladder cancer—who are candidates for NGS testing prior to first or second-line metastatic therapy, and evaluates centralized precision oncology navigation and expert NGS review to increase use of existing targeted therapies and biomarker-driven clinical trial referrals. No investigational drugs are provided; the study focuses on optimizing precision oncology care using standard of care treatments.

ClinicalTrials.gov ID: NCT06896162

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, incurable non-CNS solid tumors after progression on or intolerance to systemic therapy receive oral ETX-19477, an investigational PARG inhibitor that disrupts DNA damage repair. Enrollment preferentially considers tumors with loss-of-function BRCA2 mutations; treatment is given as monotherapy in dose-escalation and expansion cohorts.

ClinicalTrials.gov ID: NCT06395519

ASPEN-09: A Phase 1b/2, Multicenter, Multi Arm Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with metastatic HER2-positive breast cancer progressing after trastuzumab deruxtecan receive trastuzumab plus physician-selected chemotherapy with or without evorpacept, an investigational CD47 blocker that promotes macrophage engulfment of cancer cells. A separate substudy combines evorpacept with cetuximab and FOLFIRI for left-sided, microsatellite-stable, RAS/BRAF wild-type metastatic colorectal cancer progressing after first-line oxaliplatin, with no prior anti-EGFR therapy or irinotecan.

ClinicalTrials.gov ID: NCT07007559

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Adenocarcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic mismatch repair–proficient colorectal cancer or pancreatic ductal adenocarcinoma (PDAC) and a vaccine-covered KRAS mutation receive a mutant KRAS long-peptide vaccine with poly-ICLC, plus balstilimab (anti-PD-1) and botensilimab (Fc-engineered anti-CTLA-4). Cohorts include patients after 4–6 months of first-line chemotherapy and a PDAC cohort allowing up to three prior regimens, including a KRAS inhibitor.

ClinicalTrials.gov ID: NCT06411691

A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, measurable solid tumors and ECOG performance status 0–2 receive intravenous DM002 every 21 days in dose-escalation or expansion cohorts. DM002 is an investigational bispecific antibody–drug conjugate targeting MUC1 and HER3 with a topoisomerase I inhibitor payload; patients previously treated with a topoisomerase I–payload ADC are generally excluded.

ClinicalTrials.gov ID: NCT06751329

A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with selected advanced or metastatic solid tumors receive oral temozolomide plus tuvusertib (M1774), an investigational ATR inhibitor that disrupts the DNA-damage response. The expansion cohort is limited to previously treated, MGMT promoter-hypermethylated, mismatch repair-proficient/microsatellite-stable metastatic colorectal cancer; prior temozolomide or ATR inhibitor therapy is excluded.

ClinicalTrials.gov ID: NCT05691491

A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic colorectal cancer or metastatic pancreatic ductal adenocarcinoma receive oral RMC-6236, a multiselective active-RAS inhibitor, combined with fluorouracil-based chemotherapy and bevacizumab, cetuximab with or without mFOLFOX6, or gemcitabine plus nab-paclitaxel. In RAS G12D-mutant cohorts, the active-RAS G12D inhibitor RMC-9805 is given with or without RMC-6236 alongside the corresponding regimens.

ClinicalTrials.gov ID: NCT06445062

Phase I Trial of ZEN003694 (ZEN-3694) in Combination With Capecitabine in Patients With Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable solid tumors that progressed after fluoropyrimidine-containing standard therapy receive oral ZEN-3694, an investigational BET protein inhibitor, plus oral capecitabine. Dose expansion is limited to colorectal cancer.

ClinicalTrials.gov ID: NCT05803382